Analyst Ratings for Akebia Therapeutics
Portfolio Pulse from Benzinga Insights
Akebia Therapeutics (NASDAQ:AKBA) has received 5 indifferent analyst ratings in the last quarter, with an average 12-month price target of $1.7, a high of $2.00, and a low of $1.25. The average price target has increased by 36.0% over the past month.
May 26, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akebia Therapeutics has 5 indifferent analyst ratings in the last quarter, with an average 12-month price target of $1.7, up 36% in the past month.
The indifferent analyst ratings suggest that there is no strong consensus on the stock's direction. The average 12-month price target has increased by 36% over the past month, which may indicate some positive sentiment, but the overall impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100